548
Participants
Start Date
March 6, 2012
Primary Completion Date
May 25, 2018
Study Completion Date
May 25, 2018
AdCh3NSmut1
Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10\^10 total virus particles (vp)/dose, intramuscularly on day 0.
MVA-NSmut
Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.
Placebo
Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
University of New Mexico - Truman Health Services, Albuquerque
UCSF Community Research Center, San Francisco
Zuckerberg San Francisco General Hospital Unit 5B, San Francisco
University of California San Francisco - Tenderloin Clinical Research Center, San Francisco
Johns Hopkins School of Public Health - Wood Clinic, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID)
NIH